RhumbLine Advisers
MRVI icon

RhumbLine Advisers’s Maravai LifeSciences MRVI Stock Holding History

RhumbLine Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$890K Sell
142,561
-74
-0.1% -$319 ﹤0.01% 2392
2026
Q1 		$404K Sell
142,635
-7,928
-5% -$26.9K ﹤0.01% 2739
2025
Q4 		$489K Sell
150,563
-24,018
-14% -$80.9K ﹤0.01% 2677
2025
Q3 		$501K Sell
174,581
-20,691
-11% -$52.8K ﹤0.01% 2702
2025
Q2 		$471K Buy
195,272
+32,940
+20% +$69.2K ﹤0.01% 2714
2025
Q1 		$359K Sell
162,332
-22,889
-12% -$90.4K ﹤0.01% 2789
2024
Q4 		$1.01M Buy
185,221
+16,712
+10% +$108K ﹤0.01% 2242
2024
Q3 		$1.4M Sell
168,509
-2,980
-2% -$25.8K ﹤0.01% 2091
2024
Q2 		$1.23M Buy
171,489
+39,955
+30% +$345K ﹤0.01% 2136
2024
Q1 		$1.14M Sell
131,534
-14,722
-10% -$99.6K ﹤0.01% 2184
2023
Q4 		$958K Buy
146,256
+9,329
+7% +$60.3K ﹤0.01% 2275
2023
Q3 		$1.37M Sell
136,927
-22,310
-14% -$245K ﹤0.01% 2039
2023
Q2 		$1.98M Buy
159,237
+28,543
+22% +$385K ﹤0.01% 1907
2023
Q1 		$1.83M Buy
130,694
+12,463
+11% +$179K ﹤0.01% 1848
2022
Q4 		$1.69M Buy
118,231
+6,749
+6% +$106K ﹤0.01% 1869
2022
Q3 		$2.85M Buy
111,482
+5,581
+5% +$140K ﹤0.01% 1572
2022
Q2 		$3.01M Buy
105,901
+12,165
+13% +$385K ﹤0.01% 1538
2022
Q1 		$3.31M Sell
93,736
-2,692
-3% -$90.2K ﹤0.01% 1558
2021
Q4 		$4.04M Buy
96,428
+11,577
+14% +$469K 0.01% 1488
2021
Q3 		$4.16M Buy
84,851
+17,298
+26% +$844K 0.01% 1458
2021
Q2 		$2.82M Buy
67,553
+3,690
+6% +$143K ﹤0.01% 1774
2021
Q1 		$2.28M Buy
+63,863
New +$2.12M ﹤0.01% 1855

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

RhumbLine Advisers's MRVI Position: Q2 2026 in Review

RhumbLine Advisers reduced its Maravai LifeSciences (MRVI) stake by 0.05% in Q2 2026, selling an estimated $319 and leaving 142,561 shares worth $890K. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

RhumbLine Advisers first reported a position in MRVI in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.16M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • RhumbLine Advisers held 142,561 shares of Maravai LifeSciences worth $890K as of Q2 2026.
  • RhumbLine Advisers sold 74 Maravai LifeSciences shares in Q2 2026, an estimated $319.
  • Maravai LifeSciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2392 holding.
  • RhumbLine Advisers first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 22 quarters since.
  • RhumbLine Advisers's Maravai LifeSciences position peaked at $4.16M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.